Ivabradina Ampdr

Ivabradine Hydrochloride, the active ingredient in Ivabradina Ampdr, is a If channel inhibitor presented as an oral tablet for oral use. It treats chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Ampdr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Ampdr acts on the cardiac If current to manage conditions characterized by excessive heart rate.

Chronic stable angina pectoris: reduces the frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction: lowers heart rate, improving symptoms and decreasing hospitalisation risk. Coronary artery disease with sinus tachycardia: helps control heart rate, enhancing overall cardiac efficiency.

Ivabradina Ampdr may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes) especially at treatment initiation. - Bradycardia (heart rate below 50 bpm). - Headache. - Dizziness or light‑headedness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical intervention. - Atrial fibrillation or other supraventricular arrhythmias. - Marked hypotension leading to syncope. - Persistent visual impairment or retinal disturbances.

Before prescribing Ivabradina Ampdr, clinicians should consider several safety aspects. - Cardiac monitoring: patients with severe conduction disease or sick‑sinus syndrome require careful observation. - Dose adjustment: reduce dose in moderate hepatic impairment. - Avoid in: patients with acute decompensated heart failure or unstable angina. - Caution with concomitant bradycardic agents such as beta‑blockers or calcium‑channel blockers. - Pregnancy: safety category unknown; use only if potential benefit justifies risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ivabradina Ampdr can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Concomitant bradycardic agents (e.g., high‑dose beta‑blockers): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Digoxin: monitor plasma levels for potential additive effects on heart rate. - Verapamil or diltiazem: observe for enhanced bradycardia. - Antihypertensives: watch for additive hypotensive responses.